Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
Open Access
- 1 December 2016
- Vol. 34 (50) , 6436-6448
Abstract
No abstract availableKeywords
Funding Information
- European Union FP7 (103972)
- European Research Council (324634)
This publication has 55 references indexed in Scilit:
- Recombinant Salmonella enterica Serovar Typhimurium as a Vaccine Vector for HIV-1 GagViruses, 2013
- Low Seroprevalent Species D Adenovirus Vectors as Influenza VaccinesPLOS ONE, 2013
- Pre-existing immunity against vaccine vectors – friend or foe?Microbiology, 2013
- Viral vectors for vaccine applicationsClinical and Experimental Vaccine Research, 2013
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- Clinical Development of Listeria monocytogenes–Based ImmunotherapiesSeminars in Oncology, 2012
- T‐cell‐inducing vaccines – what’s the futureImmunology, 2011
- Vectors Based on Modified Vaccinia Ankara Expressing Influenza H5N1 Hemagglutinin Induce Substantial Cross-Clade Protective ImmunityPLOS ONE, 2011
- Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream productionBiotechnology Advances, 2009
- Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in MicePLOS ONE, 2008